EX-10.17





 Exhibit 10.17 

 
  

 
 SUBSCRIPTION AGREEMENT 

dated as of September 3, 2020 

by and between 
 [NAME OF
INVESTOR] 
 and 
 I-MAB 
  
  

 












 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 Article I DEFINITIONS AND INTERPRETATION
	  	 	1	 
			
	 Section 1.1
	  	Definitions	  	 	1	 
	 Section 1.2
	  	Other Defined Terms	  	 	5	 
	 Section 1.3
	  	Interpretation and Rules of Construction	  	 	5	 
		
	 Article II PURCHASE AND SALE OF SECURITIES
	  	 	6	 
			
	 Section 2.1
	  	Sale and Issuance of the Purchased Securities	  	 	6	 
	 Section 2.2
	  	Purchase Price	  	 	6	 
	 Section 2.3
	  	Closing	  	 	7	 
	 Section 2.4
	  	Contemporaneous Private Placements	  	 	8	 
		
	 Article III REPRESENTATIONS AND WARRANTIES OF THE PURCHASER
	  	 	8	 
			
	 Section 3.1
	  	Organization	  	 	8	 
	 Section 3.2
	  	Authorization; Enforcement; Validity	  	 	9	 
	 Section 3.3
	  	No Conflicts	  	 	9	 
	 Section 3.4
	  	Consents	  	 	9	 
	 Section 3.5
	  	Status and Investment Intent	  	 	9	 
	 Section 3.6
	  	Prohibited Purchaser	  	 	11	 
	 Section 3.7
	  	Brokers and Finders	  	 	12	 
	 Section 3.8
	  	No Additional Representations	  	 	12	 
		
	 Article IV REPRESENTATIONS AND WARRANTIES OF THE COMPANY
	  	 	12	 
			
	 Section 4.1
	  	Organization and Qualification	  	 	12	 
	 Section 4.2
	  	Capitalization	  	 	13	 
	 Section 4.3
	  	Authorization; Enforcement; Validity	  	 	13	 
	 Section 4.4
	  	No Conflicts	  	 	13	 
	 Section 4.5
	  	Consents	  	 	14	 
	 Section 4.6
	  	Issuance of Purchased Securities	  	 	14	 
	 Section 4.7
	  	No General Solicitation	  	 	14	 
	 Section 4.8
	  	No Integrated Offering	  	 	14	 
	 Section 4.9
	  	Public Documents	  	 	14	 
	 Section 4.10
	  	Financial Statements	  	 	15	 
	 Section 4.11
	  	No Undisclosed Liabilities	  	 	15	 
	 Section 4.12
	  	Internal Controls and Procedures	  	 	15	 


  
 i 














							
	 Section 4.13
	  	Litigation	  	 	15	 
	 Section 4.14
	  	Compliance and Permits	  	 	16	 
	 Section 4.15
	  	Tax Status	  	 	16	 
	 Section 4.16
	  	Intellectual Property	  	 	17	 
	 Section 4.17
	  	Labor and Employment Matters	  	 	17	 
	 Section 4.18
	  	Title to Property and Assets	  	 	17	 
	 Section 4.19
	  	Brokers and Finders	  	 	17	 
	 Section 4.20
	  	Anti-Bribery and Anti-Corruption; Money Laundering Laws; Economic Sanctions	  	 	17	 
	 Section 4.21
	  	License Agreement	  	 	18	 
	 Section 4.22
	  	No Materially More Favorable Terms	  	 	18	 
	 Section 4.23
	  	No Additional Representations	  	 	18	 
		
	 Article V AGREEMENTS OF THE PARTIES
	  	 	19	 
			
	 Section 5.1
	  	Further Assurances	  	 	19	 
	 Section 5.2
	  	Expenses	  	 	19	 
	 Section 5.3
	  	Confidentiality	  	 	19	 
	 Section 5.4
	  	Compliance and Other Actions Prior to Closing	  	 	20	 
	 Section 5.5
	  	Reservation of Shares	  	 	21	 
	 Section 5.6
	  	Registration Rights	  	 	21	 
	 Section 5.7
	  	Assistance in ADS Conversion	  	 	21	 
	 Section 5.8
	  	Use of Purchaser’s Name or Logo	  	 	21	 
	 Section 5.9
	  	Margin Transactions	  	 	21	 
		
	 Article VI CONDITIONS TO THE COMPANY’S OBLIGATION TO CLOSE
	  	 	21	 
			
	 Section 6.1
	  	Execution of Transaction Documents	  	 	21	 
	 Section 6.2
	  	Representations and Warranties; Covenants	  	 	22	 
	 Section 6.3
	  	No Stop Order	  	 	22	 
	 Section 6.4
	  	No Action	  	 	22	 
	 Section 6.5
	  	Purchaser Officer’s Certificates	  	 	22	 
		
	 Article VII CONDITIONS TO THE PURCHASER’S OBLIGATION TO CLOSE
	  	 	22	 
			
	 Section 7.1
	  	Execution of Transaction Documents	  	 	22	 
	 Section 7.2
	  	Representations and Warranties; Covenants	  	 	22	 
	 Section 7.3
	  	No Stop Order	  	 	23	 
	 Section 7.4
	  	No Action	  	 	23	 
	 Section 7.5
	  	No Material Adverse Effect	  	 	23	 
	 Section 7.6
	  	No Suspensions of Trading in ADSs	  	 	23	 


  
 ii 














							
	 Section 7.7
	  	License Agreement	  	 	23	 
	 Section 7.8
	  	Company Officer’s Certificate	  	 	23	 
		
	 Article VIII TERMINATION
	  	 	23	 
			
	 Section 8.1
	  	Termination	  	 	23	 
	 Section 8.2
	  	Effect of Termination	  	 	24	 
		
	 Article IX MISCELLANEOUS
	  	 	24	 
			
	 Section 9.1
	  	Survival	  	 	24	 
	 Section 9.2
	  	Indemnification	  	 	25	 
	 Section 9.3
	  	Limitation to the Indemnitor’s Liability	  	 	25	 
	 Section 9.4
	  	Governing Law	  	 	26	 
	 Section 9.5
	  	Arbitration	  	 	26	 
	 Section 9.6
	  	Counterparts	  	 	26	 
	 Section 9.7
	  	Severability	  	 	27	 
	 Section 9.8
	  	Entire Agreement	  	 	27	 
	 Section 9.9
	  	Notices	  	 	27	 
	 Section 9.10
	  	No Third-Party Beneficiaries	  	 	28	 
	 Section 9.11
	  	Successors and Assigns	  	 	28	 
	 Section 9.12
	  	Construction	  	 	28	 
	 Section 9.13
	  	Further Assurances	  	 	28	 
	 Section 9.14
	  	Adjustment of Share Numbers	  	 	28	 
	 Section 9.15
	  	Specific Performance	  	 	29	 
	 Section 9.16
	  	Amendment; Waiver	  	 	29	 


  
 iii 













 SUBSCRIPTION AGREEMENT 

THIS SUBSCRIPTION AGREEMENT (this “Agreement”), dated as of September 3, 2020, by and between
I-Mab, an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), and [Name of Investor] (the “Purchaser”). 

RECITALS 
 A. WHEREAS, the
Company desires to issue, sell and deliver to the Purchaser, and the Purchaser desires to purchase and acquire from the Company, upon the terms and conditions set forth in this Agreement, the Purchased Shares (as defined below); and 

B. WHEREAS, the Company desires to issue, sell and deliver to the Purchaser, and the Purchaser desires to purchase and acquire from the
Company, upon the terms and conditions set forth in this Agreement, the Warrant (as defined below). The Purchased Shares and the Warrant are collectively referred to herein as the “Purchased Securities”. 

NOW, THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants set forth herein and other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchaser hereby agree as follows: 

ARTICLE I 
 DEFINITIONS
AND INTERPRETATION 
 Section 1.1 Definitions. In this Agreement, except to the extent otherwise provided or that the
context otherwise requires: 
 “ADS” means American depositary shares, ten (10) of which represent twenty-three
(23) Ordinary Shares, of the Company; 
 “Affiliate” means, with respect to any specified Person, any other Person
that directly, or indirectly through one or more intermediaries, Controls, is Controlled by, or is under common Control with, such specified Person, including, without limitation, any general partner, managing member, officer, director or trustee of
such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment
adviser with, such Person; 
 “Board” means the board of directors of the Company; 

“Business Day” means any day that is not a Saturday, a Sunday or other day on which banks are required or authorized by Law
to be closed in Beijing, Cayman Islands, Hong Kong or New York; 
 “Company Share Plans” mean (a) the Company’s
Second Amended and Restated 2017 Employee Stock Option Plan, as amended; (b) the Company’s Second Amended and Restated 2018 Employee Stock Option Plan, as amended; (c) the Company’s 2019 Share Incentive Plan, as amended; and
(d) the Company’s 2020 Share Incentive Plan, as amended; 

  
 1 













 “Contract” means any agreement, contract, lease, indenture, instrument,
note, debenture, bond, mortgage or deed of trust or other agreement, commitment, arrangement or understanding; 
 “Control”
(including the terms “Controlled by” and “under common Control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether
through the ownership of voting securities, as trustee or executor, by contract or otherwise, including the ownership, directly or indirectly, of securities having the power to elect a majority of the board of directors or similar body governing the
affairs of such Person or securities that represent a majority of the outstanding voting securities of such Person; 

“Encumbrance” means any security interest, pledge, mortgage, lien, charge, claim, hypothecation, title defect, right of first
option or refusal, right of pre-emption, third-party right or interests, put or call right, lien, adverse claim of ownership or use, or other encumbrance of any kind; 

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder; 
 “GAAP” means the United States generally accepted accounting principles and applied consistently throughout
the Financial Statements; 
 “Governmental Authority” means any federal, national, foreign, supranational, state,
provincial, local, municipal or other political subdivision or other government, governmental, regulatory or administrative authority, agency, board, bureau, department, instrumentality or commission or any court, tribunal, judicial or arbitral body
of competent jurisdiction or stock exchange; 
 “knowledge” means, with respect to any party, the actual knowledge of such
party’s executive officers (as defined in Rule 405 under the Securities Act) after making such due inquiry and exercising such due diligence as a prudent business person would have made or exercised in the management of his or her business,
including inquiry of other officers or employees of such party; 
 “Law” means any federal, national, foreign,
supranational, state, provincial or local statute, law, ordinance, regulation, rule, code, order, requirement or rule of law (including common law), official policy, rule or interpretation of any Governmental Authority with jurisdiction over any of
the Company or the Purchaser; 
 “Lead Investors” means Gaoling Fund, L.P. and/or YHG Investment, L.P., including their respective
Affiliates. 

  
 2 













 “Material Adverse Effect” means any event, circumstance, development,
change or effect that, individually or in the aggregate, has or would reasonably be expected to have a material adverse effect on (a) the business, properties, assets, liabilities, operations, results of operations or financial condition of the
Company and its Subsidiaries, taken as a whole, or (b) the authority or ability of the Company to perform its obligations under the Transaction Documents; provided, however, that for purposes of clause (a) above, in no event shall
any of the following exceptions, alone or in combination with the other enumerated exceptions below, be deemed to constitute, nor shall be taken into account in determining whether there has been or will be, a Material Adverse Effect: (i) any
effect resulting from compliance with the terms and conditions of, or from the announcement of the transactions contemplated by this Agreement and/or any other Transaction Document, (ii) any effect that results from changes affecting any of the
industries in which the Company or its Subsidiaries operate generally or the economy generally, (iii) any effect that results from changes affecting general worldwide economic or capital market conditions, (iv) any pandemic, earthquake,
typhoon, tornado or other natural disaster, or similar event, (v) any event, circumstance, change or effect caused by embargoes, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of terrorism or war
(whether or not declared), including any escalation or worsening thereof; (vi) mandatorily applicable changes or modifications in the applicable general accepted accounting principles or applicable Law or the interpretation or enforcement
thereof; (vii) any failure to meet any internal or public projections, forecasts, or guidance, or (viii) any change in the Company’s stock price or trading volume, in and of itself; provided, further, that any event,
circumstance, development, change or effect referred to in the foregoing clauses (ii) through (vi) shall be taken into account in determining whether a Material Adverse Effect has occurred or could reasonably be expected to occur to the extent
that such event, circumstance, development, change or effect has a disproportionate effect on the Company and its Subsidiaries compared to other participants in the industries in which the Company and its Subsidiaries conduct their businesses;
provided, further that the underlying causes giving rise or contributing to any such failure or change in the foregoing clauses (vii) and (viii) shall not be excluded in determining whether a Material Adverse Effect has occurred.

 “Memorandum and Articles” means the Sixth Amended and Restated Memorandum and Articles of Association of the Company in
effect from time to time; 
 “Nasdaq” means the Nasdaq Stock Market LLC; 

“Ordinary Shares” means the ordinary shares of the Company, par value of US$0.0001 per share; 

“Ordinary Share Equivalents” means any Securities which would entitle the holder thereof to acquire at any time Ordinary
Shares or ADSs, including, without limitation, any debt, preferred shares, rights, options, warrants or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Ordinary Shares or ADSs; 
 “Person” means any individual, partnership, corporation, association, joint stock company,
trust, joint venture, limited liability company, organization, entity or Governmental Authority; 
 “PRC” means the
People’s Republic of China; 

  
 3 













 “Private Placements” means the contemporaneous private placements of, and
warrants to purchase, no more than 34,500,000 Ordinary Shares (without giving effect to the adjustment mechanism in the warrants) to investors (including the Purchaser) with aggregate gross proceeds of up to US$523.0 million, for which the
transaction documents are entered into between the Company and the relevant investors on or about the date hereof. 
 “Prohibited
Person” means any Person that is (1) a national or resident of any U.S. embargoed or restricted country, (2) included on, or Affiliated with any Person on, the United States Commerce Department’s Denied Parties List, Entities
and Unverified Lists; the U.S. Department of Treasury’s Specially Designated Nationals, Specially Designated Narcotics Traffickers or Specially Designated Terrorists, or the Annex to Executive Order No. 13224; the Department of
State’s Debarred List; UN Sanctions, (3) a member of any PRC military organization, or (4) a Person with whom business transactions, including exports and re-exports, are restricted by a U.S.
Governmental Authority, including, in each clause above, any updates or revisions to the foregoing and any newly published rules; 

“Public Official” means any executive, official, or employee of a Governmental Authority, political party or member of a
political party, political candidate; executive, employee or officer of a public international organization; or director, officer or employee or agent of a wholly owned or partially state-owned or controlled enterprise, including a PRC state-owned
or controlled enterprise; 
 “SEC” means the U.S. Securities and Exchange Commission; 

“Securities” means any Ordinary Shares, ADSs or any equity interest of, or shares of any class in the share capital
(ordinary, preferred or otherwise) of, the Company and any convertible securities, options, warrants and any other type of equity or equity-linked securities convertible, exercisable or exchangeable for any such equity interest or shares of any
class in the share capital of the Company; 
 “Securities Act” means the U.S. Securities Act of 1933, as amended, and the
rules and regulations promulgated thereunder; 
 “Subsidiary” of any Person means any corporation, partnership, limited
liability company, joint stock company, joint venture or other organization or entity, whether incorporated or unincorporated, which is Controlled by such Person. For all purposes of this Agreement and other Transaction Documents,
“Subsidiary” shall, with respect to the Company, as of the date hereof, include each of the entities set out in Schedule A to this Agreement; 

“Transaction Documents” mean this Agreement, the Warrant and each of the other agreements and documents entered into or
delivered by the parties hereto or their respective Affiliates in connection with the transactions contemplated by this Agreement; 

“U.S.” or “United States” means the United States of America; 

“Warrant” means the Ordinary Share subscription warrant in the form of Annex C attached hereto; and 

  
 4 













 “Warrant Shares” means the Ordinary Shares issuable upon exercise of the
Warrant. 
 Section 1.2 Other Defined Terms. The following terms shall have the meanings defined for such terms in the Sections
set forth below: 
  

			
	Agent	  	Section 5.7
	Aggregate Purchase Price	  	Section 2.2(b)
	Agreement	  	Preamble
	Allowed Delay	  	Annex A
	Bankruptcy and Equity Exception	  	Section 3.2;
	Balance Sheet	  	Section 4.11
	Closing	  	Section 2.1
	Closing Date	  	Section 2.3(a)
	Company	  	Preamble
	Company Closing Certificate	  	Section 7.8
	Compliance Laws	  	Section 4.20(a)
	Effectiveness Deadline	  	Annex A
	Financial Statements	  	Section 4.10
	HKIAC	  	Section 9.5(a)
	Indemnified Liabilities	  	Section 9.2
	Indemnitees	  	Section 9.2
	Indemnitor	  	Section 9.2
	Intellectual Property Rights	  	Section 4.16
	Judgment	  	Section 4.13
	License Agreement	  	Section 4.21
	Permits	  	Section 4.14(a)
	Placement Agent	  	Section 3.5(c)
	Proceedings	  	Section 4.13
	Prohibited Purchaser	  	Section 3.6
	Public Documents	  	Section 4.9
	Purchaser	  	Preamble
	Purchaser Closing Certificate	  	Section 6.5
	Purchased Securities	  	Preamble
	Purchased Shares	  	Section 2.1
	Purchased Shares Purchase Price	  	Section 2.2(a)
	Registrable Securities	  	Annex A
	Registration Period	  	Annex A
	Registration Rights Notice	  	Annex A
	Registration Statement	  	Annex A
	Returns	  	Section 4.15
	Rule 144	  	Annex A
	Shareholders Agreement	  	Annex A
	Tax	  	Section 4.15


 Section 1.3 Interpretation and Rules of Construction. In this Agreement, except to the
extent otherwise provided or that the context otherwise requires: 

  
 5 













 (a) when a reference is made in this Agreement to an Article or Section, such reference is
to an Article or Section of this Agreement; 
 (b) the headings for this Agreement are for reference purposes only and do not affect in any
way the meaning or interpretation of this Agreement; 
 (c) the words “hereof,” “herein” and “hereunder” and
words of similar import, when used in this Agreement, refer to this Agreement as a whole and not to any particular provision of this Agreement; 

(d) all terms defined in this Agreement have the defined meanings when used in any certificate or other document made or delivered pursuant
hereto, unless otherwise defined therein; 
 (e) the definitions contained in this Agreement are applicable to the singular as well as the
plural forms of such terms; 
 (f) references to a Person are also to its successors and permitted assigns; and 

(g) the use of the term “or” is not intended to be exclusive. 

ARTICLE II 
 PURCHASE AND
SALE OF SECURITIES 
 Section 2.1 Sale and Issuance of the Purchased Securities. Subject to the satisfaction or
waiver of the conditions set forth in Articles VI and VII below, on the Closing Date, the Company shall issue and sell to the Purchaser, and the Purchaser shall subscribe for and purchase from the Company, (i) 627,279 Ordinary Shares (the “Purchased Shares”); and (ii) a Warrant to subscribe for 115,000 Ordinary Shares (subject to adjustment as provided therein) (the “Closing”). 
 Section 2.2 Purchase Price. 

(a) Purchased Shares Purchase Price. The purchase price per Purchased Share shall be the equivalent of US$33.00 per ADS, and the
aggregate purchase price for the Purchased Shares (the “Purchased Shares Purchase Price”) shall be US$9,000,090. 
 (b)
Warrant Purchase Price. The exercise price per Warrant Share shall be the equivalent of US$45.00 per ADS, and the aggregate exercise price for the Warrant Shares (together with the Purchased Share Purchase Price, the
“Aggregate Purchase Price”) shall be US$2,250,000. 

  
 6 













 Section 2.3 Closing. 

(a) Date and Time. The Closing shall take place at 10:00 a.m., Eastern Time remotely via the exchange of documents and signatures on a
date as soon as practicable but in no event later than the fifth (5th) Business Day following the satisfaction or waiver of the conditions to the Closing set forth in Articles VI and VII below (other than those conditions that by their nature are to
be satisfied at the Closing, but subject to the satisfaction or waiver of those conditions), or such other place, date and time as may be mutually agreed in writing by the Company and the Purchaser. The date on which the Closing occurs is referred
to herein as the “Closing Date.” 
 (b) Payment and Delivery. At the Closing: 

(i) the Purchaser shall, subject to the delivery of the items by the Company to Section 2.3(b)(ii) hereunder, (A) pay the Purchased
Shares Purchase Price to the Company by electronic bank transfer of immediately available funds to a bank account specified in Schedule B (provided that a wire instruction shall have been provided by the Company to the Purchaser at
least three (3) Business Days prior to the Closing Date), and deliver to the Company a fund transmittal proof therewith; (B) deliver to the Company a scan copy of the Purchaser Closing Certificate; and (C) deliver to the Company a
copy of the Warrant duly executed by the Purchaser; provided, however, that the Purchaser shall be deemed to have satisfied its delivery obligations under this Section by making available to the Company an electronic scan copy of such Warrant
on the Closing Date and delivering the original thereof to the Company within fifteen (15) Business Days thereafter; 
 (ii) the Company
shall deliver to the Purchaser against the full payment of the Purchased Shares Purchase Price by the Purchaser pursuant to Section 2.3(b)(i) hereunder: 

(A) a share certificate representing the Purchased Shares, duly executed on behalf of the Company; provided, however, that the Company shall
be deemed to have satisfied its delivery obligations under this Section by making available to the Purchaser an electronic scan copy of such share certificate on the Closing Date and delivering the original thereof to the Purchaser within fifteen
(15) Business Days thereafter; 
 (B) a scan copy of an extract of the register of members of the Company dated as of the Closing Date,
reflecting the Purchaser’s ownership of the Purchased Shares, duly certified by the registered agent of the Company; 
 (C) a scan copy
of the resolutions of the Board approving the entering into and execution of this Agreement, the issuance of the Purchased Securities, the issuance of the Warrant Shares upon exercise of the Warrant by the Purchaser, the entering into and execution
of the other Transaction Documents to which the Company is a party, and the consummation of all transactions contemplated herein and therein, duly certified by a director of the Company; 

(D) an opinion of Conyers Dill & Pearman, Cayman Islands counsel to the Company, in relation to the Purchased Securities and the
Warrant Shares, substantially in the form attached hereto as Annex B; 
 (E) a scan copy of the Company Closing Certificate; and 


  
 7 













 (F) a copy of the Warrant duly executed by and on behalf of the Company and dated the
Closing Date; provided, however, that the Company shall be deemed to have satisfied its delivery obligations under this Section by making available to the Purchaser an electronic scan copy of such Warrant on the Closing Date and delivering
the original thereof to the Purchaser within fifteen (15) Business Days thereafter. 
 (c) Restrictive Legend. Each certificate
representing any of the Purchased Securities shall be endorsed with the following legend: 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED EXCEPT IN ACCORDANCE WITH THE PROVISIONS OF REGULATION S PROMULGATED UNDER THE SECURITIES
ACT, PURSUANT TO REGISTRATION UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION. HEDGING TRANSACTIONS INVOLVING THE SECURITIES REPRESENTED HEREBY MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT. THIS
CERTIFICATE MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE OR ANY OTHER TRANSFER OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE. 

Section 2.4 Contemporaneous Private Placements. The Purchaser agrees and acknowledges that its investment in the Purchased
Securities contemplated hereunder is part of the Private Placements; provided that the sale and issuance of the Purchased Securities shall only be subject to such closing conditions as expressly provided hereunder. 

ARTICLE III 

REPRESENTATIONS AND WARRANTIES OF THE PURCHASER 

The Purchaser represents and warrants to the Company as of the date hereof and as of the Closing Date that: 

Section 3.1 Organization. The Purchaser is an exempted company with limited liability duly incorporated, organized, validly
existing and in good standing under the Laws of Cayman Islands. The Purchaser has all requisite power and authority to carry on its business as it is currently being conducted. 

  
 8 













 Section 3.2 Authorization; Enforcement; Validity. The Purchaser has the
requisite corporate power and authority to execute and deliver this Agreement and the other Transaction Documents to which it is a party and perform its obligations under this Agreement and the other Transaction Documents to which it is a party. The
execution, delivery and performance of this Agreement and the other Transaction Documents to which it is a party and the consummation of the transactions contemplated hereby and thereby have been duly and validly authorized by all requisite
corporate action by the Purchaser and no other actions or proceedings on the part of the Purchaser is necessary to authorize the execution and delivery by it of this Agreement, the performance by it of its obligations hereunder or the consummation
by it of the transactions contemplated by this Agreement. This Agreement and the other Transaction Documents to which it is a party have been or will be duly executed and delivered by the Purchaser, and, assuming the due authorization, execution and
delivery by the Company, constitutes a legal, valid and binding obligation of the Purchaser, enforceable against the Purchaser in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and
similar Laws of general applicability relating to or affecting creditors’ rights and to general equity principles (the “Bankruptcy and Equity Exception”). 

Section 3.3 No Conflicts. The execution, delivery and performance by the Purchaser of this Agreement and the consummation by the
Purchaser of the transactions contemplated hereby will not (a) result in a violation of the organizational or constitutional documents of the Purchaser, (b) conflict with, or constitute a default (or an event which with notice or lapse of
time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of any Contract to which the Purchaser is a party, or (c) result in a violation of any Law applicable to the
Purchaser, except in the case of clauses (b) and (c) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, have a material adverse effect on the ability of the Purchaser to perform its
obligations hereunder. 
 Section 3.4 Consents. In connection with the entering into and performance of this Agreement and the
other Transaction Documents, the Purchaser is not required to obtain any consent, authorization or order of, or make any filing or registration with, (a) any Governmental Authority in order for it to execute, deliver or perform any of its
obligations under or contemplated hereby or thereby or (b) any third party pursuant to any agreement, indenture or instrument to which the Purchaser is a party, in each case in accordance with the terms hereof or thereof other than such as have
been made or obtained. 
 Section 3.5 Status and Investment Intent.  

(a) Status of the Purchaser. The Purchaser is, and on each date on which it exercises the Warrant, will be (i) an “accredited
investor” within the meaning of Rule 501 of Regulation D under the Securities Act and/or (ii) not a “U.S. person” within the meaning of Regulation S under the Securities Act. 

(b) Experienced Investor. The Purchaser has sufficient knowledge and experience in financial and business matters so as to be capable of
evaluating the merits and risks of its investment in the Purchased Securities and the Warrant Shares. The Purchaser is capable of bearing the economic risks of such investment, including a complete loss of its investment. 

  
 9 













 (c) Access to Information. The Purchaser acknowledges that it has had the opportunity
to review the Transaction Documents (including all annexes, exhibits and schedules thereto) and the Public Documents and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from,
representatives of the Company concerning the terms and conditions of the offering of the Purchased Securities and the Warrant Shares and the merits and risks of investing in the Purchased Securities and the Warrant Shares; (ii) access to
information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information
that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment. The Purchaser has sought such accounting, legal and tax advice as it has
considered necessary to make an informed decision with respect to its acquisition of the Purchased Securities and the Warrant Shares. The Purchaser hereby acknowledges and agrees that it has independently evaluated the merits of its decision to
purchase the Purchased Securities and the Warrant Shares, and that (A) Jefferies LLC (the “Placement Agent”) is acting solely as placement agent in connection with the execution, delivery and performance of the Transaction
Documents and is not acting as underwriter or in any other capacity and is not and shall not be construed as a fiduciary for the Purchaser, the Company or any other Person in connection with the execution, delivery and performance of the Transaction
Documents, (B) the Purchaser has not relied on the Placement Agent or its officers, directors, employees, attorneys or Affiliates with respect to the negotiation, execution or performance of the Transaction Documents or any representation or
warranty made by any of the foregoing Persons in, in connection with, or as an inducement to the Transaction Documents, (C) the Placement Agent will not have any responsibility with respect to any representations, warranties or agreements made
by any person or entity under or in connection with the Transaction Documents, and (D) the Placement Agent will not have any liability or obligation (including without limitation, for or with respect to any losses, claims, damages, obligations,
penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by the Purchaser, whether in contract, tort or otherwise, arising out of or connection with the Transaction Documents absent gross negligence or willful misconduct
(other than an action or failure to act undertaken at the request or with the express consent of the Purchaser) on the part of the Placement Agent. 

(d) No Public Sale or Distribution. The Purchaser is acquiring the Purchased Securities and will acquire the Warrant Shares upon
exercise of the Warrant for its own account and not on behalf of any U.S. person and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the
Securities Act. The Purchaser does not presently have any agreement or understanding, directly or indirectly, with any Person to distribute any of the Purchased Securities or the Warrant Shares upon exercise of the Warrant. The Purchaser is not a
broker-dealer registered with the SEC under the Exchange Act or an entity engaged in a business that would require it to be so registered as a broker-dealer. 

(e) Solicitation. The Purchaser did not contact the Company as a result of any general solicitation or directed selling efforts (within
the meaning of Regulation S promulgated under the Securities Act). 
 (f) Offshore Transaction. The Purchaser has been advised and
acknowledges that in issuing the Purchased Securities and the Warrant Shares to the Purchaser pursuant to this Agreement and the other Transaction Documents, the Company is relying upon the exemption from registration provided by Regulation S under
the Securities Act. The Purchaser is acquiring the Purchased Securities and will acquire the Warrant Shares upon exercise of the Warrant in an offshore transaction executed in reliance upon the exemption from registration provided by Regulation S
under the Securities Act. The Purchaser acknowledges that at the time of the origination of contact concerning this Agreement and the date of the execution and delivery of this Agreement, the Purchaser was outside of the United States. 

  
 10 













 (g) Reliance on Exemptions; Restricted Securities. The Purchaser understands that the
Purchased Securities and the Warrant Shares are being offered and sold to it in reliance on specific exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon the
truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser set forth herein in order to determine the availability of such exemptions and the
eligibility of the Purchaser to acquire the Purchased Securities and the Warrant Shares. The Purchaser acknowledges that the Purchased Securities are, and the Warrant Shares when issued upon exercise of the Warrant will be, “restricted
securities” that have not been, and will have not been, registered under the Securities Act or any applicable state securities Law. The Purchaser further acknowledges that, absent an effective registration under the Securities Act, the
Purchased Securities and the Warrant Shares may only be offered, sold or otherwise transferred (i) to the Company or any Subsidiary thereof, (ii) outside the United States in accordance with Rule 904 of Regulation S under the Securities
Act or (iii) pursuant to an exemption from registration under the Securities Act. 
 (h) No Public Market. The Purchaser
understands that no public market now exists for the Warrant, and that the Company has made no assurances that a public market will ever exist for the Warrant. 

Section 3.6 Prohibited Purchaser. The Purchaser represents that neither it nor, to its knowledge, its Affiliates, nor any Person
having a beneficial interest in it, nor any Person on whose behalf the Purchaser is acting (i) a Person that is currently the subject of Sanctions; (ii) is a non-U.S. shell bank or is providing
banking services indirectly to a non-U.S. shell bank; (iii) is a senior non-U.S. political figure or an immediate family member or close associate of such figure;
or (iv) is otherwise prohibited from investing in the Company pursuant to applicable money laundering laws, anti-terrorist and asset control laws, regulations, rules or orders (categories (i) through (iv), each a “Prohibited
Purchaser”). The Purchaser agrees to provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply with applicable money laundering laws, anti-terrorist and asset control
laws, regulations, rules and orders, within the constraints imposed on such Purchaser and its Affiliates by applicable Law, organization documents or existing internal policies. The Purchaser consents to the disclosure to regulators and law
enforcement authorities by the Company and its Affiliates and agents of such information about the Purchaser as the Company reasonably deems necessary or appropriate to comply with applicable money laundering laws, anti-terrorist and asset control
laws, regulations, rules and orders; provided, however, that nothing in this Agreement shall be construed as requiring the Purchaser to provide or disclose any non-public information with respect
to it or any of its Affiliates other than of the type or to the extent the Purchaser and/or its Affiliates have previously provided to regulators and law enforcement authorities in prior transactions under substantially similar standards of
confidentiality. If the Purchaser is a financial institution that is subject to the USA Patriot Act, the Purchaser represents that it has met all of its obligations under the USA Patriot Act. The Purchaser acknowledges that if, following its
investment in the Company, the Company reasonably believes that the Purchaser is a Prohibited Purchaser, the Company has the right or may be obligated to prohibit additional investments, segregate the assets constituting the investment in accordance
with applicable regulations or immediately require the Purchaser to transfer the Purchased Securities and the Warrant Shares. 

  
 11 













 Section 3.7 Brokers and Finders. Neither the Purchaser nor any of its Affiliates
is a party to any agreement, arrangement or understanding with any Person that would give rise to any valid right, interest or claim against or upon the Company or the Purchaser for any brokerage commission, finder’s fee or other similar
compensation, as a result of the transactions contemplated by the Transaction Documents. 
 Section 3.8 No Additional
Representations. The Purchaser acknowledges that the Company makes no representations or warranties as to any matter whatsoever except as expressly set forth in this Agreement or in any certificate delivered by the Company to the Purchaser in
accordance with the terms hereof and thereof. Nothing herein shall be deemed to limit any of the Purchaser’s claims relating to fraud, intentional concealment of material facts or other willful misconduct. 

ARTICLE IV 

REPRESENTATIONS AND WARRANTIES OF THE COMPANY 

The Company represents and warrants to the Purchaser as of the date hereof and as of the Closing Date that, except as set forth in its Public
Documents filed prior to the date of this Agreement (without giving effect to any amendment thereto filed on or after the date of this Agreement and excluding (i) disclosures of non-specific risks faced
by the Company included in any forward-looking statement, disclaimer, risk factor disclosure or other similarly non-specific statements that are predictive, general or forward-looking in nature; and
(ii) disclosures in any Public Documents filed after the date of this Agreement but are incorporated by reference into the Public Documents filed prior to or on the date of this Agreement): 

Section 4.1 Organization and Qualification. The Company is an exempted company with limited liability duly incorporated,
organized, validly existing and in good standing under the Laws of the Cayman Islands, and has the requisite corporate power and authorization to own, lease and operate its properties and to carry on its business as now being conducted. Each
Subsidiary of the Company has been duly organized, is validly existing and in good standing (with respect to jurisdictions that recognize the concept of good standing) under the Laws of its jurisdiction of organization, and has the requisite
corporate power and authorization to own, lease and operate its properties and to carry on its business as now being conducted. Each of the Company and each of its Subsidiaries is duly qualified or licensed to do business in each jurisdiction in
which the property owned, leased or operated by it or the nature of the business conducted by it makes such qualification or licensing necessary, except where the failure to be so qualified or licensed would not, individually or in the aggregate, be
or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. None of the Company or its Subsidiaries is in violation of any of the provisions of its constitutional documents in any material respects. 

  
 12 













 Section 4.2 Capitalization. As of the date of this Agreement, the authorized
share capital of the Company is US$80,000 divided into 800,000,000 ordinary shares of a par value of US$0.0001 each, which shall have the rights as determined by the Board in accordance with the Memorandum and Articles. As of the date of this
Agreement, 133,006,644 Ordinary Shares are issued and outstanding. As of the date of this Agreement, 31,475,485 Ordinary Shares have been reserved for issuance under the Company Share Plans, and options to purchase 26,704,628 Ordinary Shares have
been granted and outstanding under the Company Share Plans. All outstanding Ordinary Shares are duly authorized, validly issued, fully paid and non-assessable and not subject to preemptive rights. The Warrant
Shares issuable upon the exercise of the Warrant have been duly and validly reserved for issuance. When issued in compliance with the provisions of this Agreement and the Warrant, as applicable, and the Memorandum and Articles, the Warrant
Shares will be (i) validly issued, fully paid and nonassessable, (ii) issued in compliance with the applicable registration and qualification requirements of applicable Laws, and (iii) will be free from all rights of first refusal,
preemptive or similar rights, Taxes and Encumbrances; provided, however, that the Warrant Shares may be subject to restrictions on transfer under the applicable securities Laws. 

Section 4.3 Authorization; Enforcement; Validity. The Company has the requisite corporate power and authority to execute and
deliver this Agreement and the other Transaction Documents and perform its obligations under this Agreement and the other Transaction Documents and to issue the Purchased Securities in accordance with the terms hereof. The execution, delivery and
performance of this Agreement and the other Transaction Documents and the consummation of the transactions contemplated hereby and thereby, including, without limitation, the issuance of the Purchased Securities, have been duly and validly
authorized by all requisite corporate action by the Company and no other actions or proceedings on the part of the Company is necessary to authorize the execution and delivery by it of this Agreement and the other Transaction Documents, the
performance by it of its obligations hereunder and thereunder or the consummation by it of the transactions contemplated by this Agreement and the other Transaction Documents. This Agreement and the other Transaction Documents have been or will be
duly executed and delivered by the Company, and, assuming the due authorization, execution and delivery by the Purchaser, constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms,
subject to the Bankruptcy and Equity Exception. 
 Section 4.4 No Conflicts. The execution, delivery and performance by the
Company of this Agreement and the other Transaction Documents and the consummation by the Company of the transactions contemplated hereby and thereby (including, the issuance of the Purchased Securities and the Warrant Shares) will not
(a) result in a violation of the Memorandum and Articles or any other organizational or constitutional documents of the Company or the constitutional documents of any of the Company’s Subsidiaries, (b) conflict with, or constitute a
default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any material Contract to which the Company or any Subsidiary of
its Subsidiaries is a party, or (c) result in a material violation of any Law applicable to the Company or its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries is bound or affected), except in the case of
clause (b) above, for such conflicts, defaults, or rights which would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. 

  
 13 













 Section 4.5 Consents. In connection with the entering into and performance of
this Agreement and the other Transaction Documents, the Company or any of its Subsidiary is not required to obtain any consent, authorization or order of, or make any filing or registration with, (a) any Governmental Authority in order for it
to execute, deliver or perform any of its obligations under or contemplated hereby or thereby, except for any required filing or notification under applicable securities Laws regarding the issuance of the Purchased Securities and the Warrant Shares,
or (b) any third party pursuant to any agreement, indenture or instrument to which the Company is a party, in each case in accordance with the terms hereof or thereof other than such as have been made or obtained. 

Section 4.6 Issuance of Purchased Securities. The Purchased Shares are duly and validly authorized for issuance and sale to
the Purchaser by the Company, and, when issued and delivered by the Company against payment therefor by the Purchaser in accordance with the terms hereof, shall be validly issued and non-assessable and free
from all rights of first refusal, preemptive or similar rights, Taxes and Encumbrances and the Purchased Shares shall be fully paid with the Purchaser being entitled to all rights accorded to a holder of the Ordinary Shares. The Warrant is duly and
validly authorized for issuance and sale to the Purchaser by the Company, and will be a legally binding and valid obligation of the Company and enforceable against the Company in accordance with its terms, subject to the Bankruptcy and Equity
Exception. Assuming the accuracy of the representations and warranties set forth in Section 3.5 of this Agreement, the offer and issuance by the Company of the Purchased Securities is exempt from registration under the Securities Act. 

Section 4.7 No General Solicitation. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf,
has engaged in any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) or directed selling efforts (within the meaning of Regulation S promulgated under the Securities Act) in
connection with the offer or sale of the Purchased Securities. 
 Section 4.8 No Integrated Offering. None of the Company, any
of its Affiliates, or any Person acting on their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration of the issuance of any of
the Purchased Securities under the Securities Act, whether through integration with prior offerings or otherwise. 
 Section 4.9
Public Documents. The Company has timely filed or furnished, as applicable, all reports, schedules, forms, statements and other documents required to be filed or furnished by it with the SEC pursuant to the Securities Act or the Exchange Act
(all of the foregoing documents filed with or furnished to the SEC on or prior to the date hereof and all exhibits included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being
hereinafter referred to as the “Public Documents”). As of their respective filing or furnishing dates, the Public Documents complied in all material respects with the requirements of the Securities Act or the Exchange Act, as the
case may be, and the rules and regulations of the SEC promulgated thereunder, as applicable, to the respective Public Documents, and, other than as corrected or clarified in a subsequent Public Document, none of the Public Documents, at the time
they were filed or furnished, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading. 

  
 14 













 Section 4.10 Financial Statements. As of their respective dates, the financial
statements of the Company included in the Public Documents (the “Financial Statements”) complied as to form in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with
respect thereto. The Financial Statements (including any related notes thereto) fairly present in all material respects the consolidated financial position of the Company as of the dates indicated therein and the consolidated results of its
operations, cash flows and changes in shareholders’ equity for the periods specified therein, other than as corrected or clarified in a subsequent Public Document. The Financial Statements were prepared in accordance with GAAP applied on a
consistent basis (except (a) as may be otherwise indicated in such financial statements or the notes thereto, or (b) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed to summary
statements). 
 Section 4.11 No Undisclosed Liabilities. The Company and its Subsidiaries do not have any liabilities or
obligations other than (a) liabilities or obligations reflected on, reserved against, or disclosed in the Company’s latest balance sheet (the “Balance Sheet”) as disclosed in the Public Documents (excluding those
discharged or paid in full prior to the date of this Agreement), (b) liabilities not required to be reflected in the Company’s financial statements pursuant to GAAP or disclosed in filings made with the SEC, and (c) liabilities incurred
since the date of the Balance Sheet in the ordinary course of business consistent with past practices and any liabilities incurred pursuant to this Agreement that are not material to the Company and its Subsidiaries, taken as a whole. 

Section 4.12 Internal Controls and Procedures. The Company is in compliance with any and all applicable requirements of the
Sarbanes-Oxley Act of 2002 that are effective as of the date hereof, and any and all applicable rules and regulations promulgated by the SEC thereunder that are effective as of the date hereof. Except as disclosed in the Public Documents, the
Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability, (iii) access to assets is permitted only in accordance with management’s general
or specific authorization, and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. 

Section 4.13 Litigation. Neither the Company nor any of its Subsidiaries, nor any of their directors or officers, is a party to
any, and there are no pending or, to the Company’s knowledge, threatened, legal, administrative, arbitral or other claims, suits, actions or proceedings or governmental or regulatory investigations (“Proceedings”) of any nature
(i) against the Company or any of its Subsidiaries or to which any of their interests or material properties or assets is subject, except for any Proceedings which, in each case, would not, individually or in the aggregate, be or reasonably
expected to be material to the Company and its Subsidiaries, taken as a whole , or (ii) any Proceedings that seek to restrain or enjoin the consummation of the transactions contemplated by the Transaction Documents. There is no judgment, order,
injunction or decree (“Judgment”) outstanding against Company, any of its Subsidiaries, any of their equity interests, material properties or assets, or any of their directors and officers (in their capacity as directors and
officers), except for any Judgment which would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole . 

  
 15 













 Section 4.14 Compliance and Permits. 

(a) The Company and each of its Subsidiaries have all permits, licenses, authorizations, consents, orders and approvals (collectively,
“Permits”) of, and have made all filings, applications and registrations with, any Governmental Authority that are required in order to carry on their business as presently conducted, except where the failure to have such Permits or
the failure to make such filings, applications and registrations would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole; and all such Permits are in full force and
effect and, to the knowledge of the Company, no suspension or cancellation of any of them is threatened, and all such filings, applications and registrations are current, except where such absence, suspension or cancellation would not, individually
or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. 
 (b) The Company is
not in violation of any listing requirements of the Nasdaq and has no knowledge of any facts that would reasonably be expected to lead to delisting or suspension of its ADSs from the Nasdaq in the foreseeable future. 

Section 4.15 Tax Status. The Company and each of its Subsidiaries (a) has made or filed in a timely manner (within any
applicable extension periods) and in the appropriate jurisdictions all foreign, federal and state income and all other tax returns, reports, information statements and other documentation (including any additional or supporting materials) required
to be filed or maintained in connection with the calculation, determination, assessment or collection of any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties, governmental fees and charges of whatever kind (each
a “Tax”), including all amended returns required as a result of examination adjustments made by any Governmental Authority responsible for the imposition of any Tax (collectively, the “Returns”), and such Returns
are true, correct and complete in all material respects, (b) has paid all Taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such Returns, except those being contested in good
faith, not finally determined, and (c) has set aside on its books provision reasonably adequate for the payment of all Taxes for periods subsequent to the periods to which such Returns apply. Neither the Company nor any of its Subsidiaries has
received notice regarding unpaid Taxes in any material amount claimed to be due by the taxing authority of any jurisdiction and the Company is not aware of any reasonable basis for such claim. 

  
 16 













 Section 4.16 Intellectual Property. The Company and the Subsidiaries own,
possess, license or have other rights to use or can acquire on reasonable terms all material patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other
intellectual property rights and similar rights necessary or required for use in connection with their respective businesses as described in the Public Documents (collectively, the “Intellectual Property Rights”). Neither the
Company nor any Subsidiary has received, since the date of the Balance Sheet, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as would not,
individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. To the knowledge of the Company, all such Intellectual Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property Rights that would, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. 

Section 4.17 Labor and Employment Matters. No labor disturbance by or dispute with the employees of the Company or its
Subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its Subsidiaries’ principal
suppliers, contractors or customers, except as would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. 

Section 4.18 Title to Property and Assets. Each of the Company and its Subsidiaries has good and marketable title to, or a legal
and valid right to use, all properties and assets (whether tangible or intangible) that it purports to own (including as reflected in the Balance Sheet) or that it uses, free and clear of any and all Encumbrances, except for any defects in title or
right or any Encumbrances that would not, individually or in the aggregate, be or reasonably expected to be material to the Company and its Subsidiaries, taken as a whole. Such properties and assets collectively represent in all material respects
all properties and assets necessary for the conduct of the business of the Company and its Subsidiaries as presently conducted. 

Section 4.19 Brokers and Finders. The Company shall be responsible for the placement agent fees and reimbursement payable to the
Placement Agent in connection with the sale of the Purchased Securities. Other than the Placement Agent, neither the Company nor any of its Affiliates is a party to any agreement, arrangement or understanding with any Person that would give rise to
any valid right, interest or claim against or upon the Purchaser or the Company for any brokerage commission, finder’s fee or other similar compensation, as a result of the transactions contemplated by the Transaction Documents. 

Section 4.20 Anti-Bribery and Anti-Corruption; Money Laundering Laws; Economic Sanctions. 

(a) The Company and its Subsidiaries and their respective directors, officers, employees, and to the knowledge of the Company, agents and other
persons acting on their behalf are and have been in compliance with all applicable Laws relating to antibribery, anti-corruption, anti-money laundering, record keeping and internal control laws (collectively, the “Compliance Laws”).
Furthermore, no Public Official (i) holds an ownership or other economic interest, direct or indirect, in any of the Company or its Subsidiaries or in the contractual relationship formed by this Agreement, or (ii) serves as an officer,
director or employee of any of the Company or its Subsidiaries. 

  
 17 













 (b) None of the Company or its Subsidiaries or any of their respective directors, officers,
employees, or to the knowledge of the Company, agents and other persons acting on their behalf has been found by a Governmental Authority to have violated any criminal or securities Law or is subject to any indictment or any government investigation
for bribery. None of the beneficial owners of a substantial portion of equity securities or other interest in any of the Company or its Subsidiaries or the current or former directors, officers or employees of any of the Company and its
Subsidiaries, or to the knowledge of the Company, agents or other persons acting on the Company’s or its Subsidiaries’ behalf, are or were Public Officials. 

(c) None of the Company or its Subsidiaries or any of their respective directors, officers, employees, or to the knowledge of the Company,
agents and other persons acting on their behalf is a Prohibited Person, and no Prohibited Person will be given an offer to become an employee, officer, consultant or director of any of the Company or its Subsidiaries. None of the Company or its
Subsidiaries has conducted or agreed to conduct any business, or entered into or agreed to enter into any transaction with a Prohibited Person. 

Section 4.21 License Agreement. On or prior to the date hereof, the Company shall have entered into a license agreement (the
“License Agreement”) with respect to the out-licensing of certain assets of the Company. 

Section 4.22 No Materially More Favorable Terms. The Company has not entered into any definitive transaction document, side
letter, undertaking letter or other similar agreement or instrument with any other investor in connection with the Private Placements with terms and conditions that are materially more favorable than the terms and conditions provided hereunder;
provided that the Company has provided certain separate terms to the Lead Investors, including without limitation, lock-up requirement and board seat. 

Section 4.23 No Additional Representations. The Company acknowledges that the Purchaser makes no representations or warranties as
to any matter whatsoever except as expressly set forth in this Agreement or in any certificate delivered by the Purchaser to the Company in accordance with the terms hereof and thereof. Nothing herein shall be deemed to limit any of the
Company’s claims relating to fraud, intentional concealment of material facts or other willful misconduct. 

  
 18 













 ARTICLE V 

AGREEMENTS OF THE PARTIES 

Section 5.1 Further Assurances. The Purchaser and the Company shall use its reasonable best efforts to fulfill or obtain the
fulfillment of the conditions precedent to the consummation of the transactions contemplated by this Agreement on a timely basis, including the execution and delivery of any documents, certificates, instruments or other papers that are reasonably
required for the consummation of such transactions, and will cooperate and consult with the other and use its reasonable best efforts to prepare and file all necessary documentation, to effect all necessary applications, notices, petitions, filings
and other documents, and to obtain all necessary Permits of, or any exemption by, all Governmental Authorities, necessary or advisable to consummate the transactions contemplated by this Agreement. During the period from the date of this Agreement
through the Closing Date, except as required by applicable Law or with the prior written consent of the other party, each of the Purchaser and the Company will use reasonable best effort to avoid taking any action which, or failing to take any
action the failure of which to be taken, would, or would reasonably be expected to (a) result in any of the representations and warranties set forth in Article III or IV on the part of the party taking or failing to take such action being or
becoming untrue in any respect, (b) result in any conditions set forth in Articles VI and VII not to be satisfied, or (c) result in any material violation of any provision of this Agreement. After the Closing Date, each party shall use
reasonable best efforts to execute and deliver such further certificates, agreements and other documents and take such other actions as the other party may reasonably request to consummate or implement such transactions or to evidence such events or
matters. 
 Section 5.2 Expenses. Except as otherwise provided in this Agreement and the other Transaction Documents, each party
shall bear and pay its own costs, fees and expenses incurred by it in connection with the Transaction Documents and the transactions contemplated by the Transaction Documents. 

Section 5.3 Confidentiality .  

(a) Each party shall keep confidential any non-public material or information with respect to the
business operations, financial conditions, and other aspects of the other parties which it is aware of, or have access to, in signing or performing this Agreement and the other Transaction Documents (including written or non-written information, the “Confidential Information”). Confidential Information shall not include any information that is (a) previously known on a
non-confidential basis by the receiving party, (b) in the public domain through no fault of such receiving party, its Affiliates or its or its Affiliates’ officers, directors or employees,
(c) received from a party other than the Company or the Company’s representatives or agents, so long as such party was not, to the knowledge of the receiving party, subject to a duty of confidentiality to the Company or (d) developed
independently by the receiving party without reference to confidential information of the disclosing party. No party shall disclose such Confidential Information to any third party. Any Party may use the Confidential Information only for the purpose
of, and to the extent necessary for performing this Agreement and the other Transaction Documents; and shall not use such Confidential Information for any other purposes. The parties hereby agree, for the purpose of this Section 5.3, that the
existence and terms and conditions of this Agreement and exhibits hereof shall be deemed as Confidential Information. 

  
 19 













 (b) Notwithstanding any other provisions in this Section 5.3, if any party believes in
good faith that any announcement or notice must be prepared or published pursuant to applicable Laws (including any rules or regulations of any securities exchange or valid legal process) or information is otherwise required to be disclosed to any
Governmental Authority (including any filings made with, or any information furnished to, the SEC) with respect to this Agreement or the other Transaction Documents and the transactions contemplated hereby and thereby, such party may, in accordance
with its understanding of the applicable Laws, make the required disclosure in the manner it deems in compliance with the requirements of applicable Laws; provided that the parties, to the extent permitted by applicable Law, will consult with
each other before issuance, and provide each other the opportunity to review, comment upon and concur with, and use all reasonable efforts to agree on any press release, public statement, or disclosure in the filings made with, or any information
furnished to, the SEC, with respect to this Agreement or the other Transaction Documents and the transactions contemplated hereby and thereby, and will not (to the extent practicable) issue any such press release or make any such public statement or
filings, or furnish such information, prior to such consultation and agreement, except as may be required by Law or any listing agreement with or requirement of the Nasdaq or any other applicable securities exchange, provided that the disclosing
party shall, to the extent permitted by applicable Law or any listing agreement with or requirement of the Nasdaq or any other applicable securities exchange and if reasonably practicable, inform the other party about the disclosure to be made
pursuant to such requirements prior to the disclosure and provide the other party the opportunity to review such disclosure. 
 (c) Each
party may disclose the Confidential Information only to its Affiliates and its and its Affiliates’ officers, directors, managers, partners, employees, agents, legal advisors and representatives on a need-to-know basis in the performance of the Transaction Agreements; provided that, such party shall ensure such Persons strictly abide by the confidentiality obligations hereunder or substantially
equivalent terms. 
 (d) The confidentiality obligations of each party hereunder shall survive the termination of this Agreement. Each party
shall continue to abide by the confidentiality clause hereof and perform the obligation of confidentiality it undertakes until the other party approves release of that obligation or until a breach of the confidentiality clause hereof will no longer
result in any prejudice to the other party. 
 Section 5.4 Compliance and Other Actions Prior to Closing. Except for the
transactions contemplated under this Agreement, the other Transaction Documents and the Private Placements, from the date hereof until the Closing Date, the Company shall, and shall cause each of its Subsidiaries to, (a) conduct its business
and affairs in the ordinary course of business consistent with past practice or its business expansion plans as disclosed in the Public Documents, (b) not take any action, or omit to take any action, that would reasonably be expected to make
(x) any of its representations and warranties in this Agreement untrue, or (y) any of the conditions for the benefit of the Purchaser set forth in Article VII not to be satisfied, in each case, at, or as of any time before, the Closing
Date. Without limiting the generality of the foregoing, the Company agrees that, except as disclosed in the Public Documents, from the date hereof until the Closing Date, none of the Company or its Subsidiaries shall make (or otherwise enter into
any Contract with respect to) (a) any material change in any method of accounting or accounting practice by the Company or any of its Subsidiaries; (b) any declaration, setting aside or payment of any dividend or other distribution with
respect to any Securities of the Company or any of its Subsidiaries (except for dividends or other distributions by any Subsidiary to the Company or to any of the Company’s wholly owned Subsidiaries); (c) any redemption, repurchase or other
acquisition of any share capital of the Company or any of its Subsidiaries; (d) issue or sell any Securities or debt securities, warrants or other rights to acquire any Security other than pursuant to the transactions contemplated under the
Private Placements or the Company Share Plans; or (e) make any alteration or amendment to the Memorandum and Articles, or change the size or composition of the Board or any committee thereof. The Company does not currently intend to use any
portion of the proceeds from the Aggregate Purchase Price to (i) pay dividend in cash or in kind to, (ii) make distributions in any form to, (iii) repurchase or redeem Securities from, or (iv) otherwise make payments to, any
holder of Securities. 

  
 20 













 Section 5.5 Reservation of Shares. The Company shall maintain a reserve from its
duly authorized but unissued shares, sufficient Ordinary Shares to enable the Company to comply with its obligations to issue the Purchased Shares and the Warrant Shares. 

Section 5.6 Registration Rights. The Purchaser shall be entitled to the registration rights with respect to the Registrable
Securities held thereby as set forth in Annex A attached hereto. 
 Section 5.7 Assistance in ADS Conversion. Upon
written request by the Purchaser, the Company shall provide reasonable assistance to the Purchaser in the sale, resale or other disposition of the Purchased Shares and the Warrant Shares (if any), including the conversion of the Purchased Shares and
the Warrant Shares (if any) into freely tradeable ADSs, subject to the rules and regulations of the Securities Act. The Company shall make reasonable best efforts to: (a) request its counsel to submit a request, and if requested, an opinion, to
the Company’s depositary, the corporate registrar, and transfer agent and all other applicable parties (as applicable, collectively “Agent”) to facilitate the removal of all restrictive legends or any other forms of
restrictions on the Purchased Shares and the Warrant Shares (if any) and the conversion of the Purchased Shares and the Warrant Shares (if any) into freely tradeable ADSs, subject to the rules and regulations of the Securities Act, and
(b) provide conversion approvals and instructions to the Agent and all other applicable parties (as applicable). 
 Section 5.8
Use of Purchaser’s Name or Logo. Without the prior written consent of the Purchaser (regardless of whether the Purchaser then holds any Securities), the Company shall not and shall cause each of its Affiliates not to use,
publish or reproduce the name of the Purchaser or its Affiliates or any similar name, trademark or logo in any of their marketing, advertising or promotion materials or otherwise for any marketing, advertising or promotional purposes. 

Section 5.9 Margin Transactions. The Company acknowledges and agrees that, notwithstanding anything herein to the contrary, the
Purchased Shares may be pledged by the Purchaser in connection with a bona fide margin agreement, and Purchaser effecting a pledge of Purchased Shares shall not be required to provide the Company with any notice thereof or otherwise make any
delivery to the Company pursuant to this Agreement. 
 ARTICLE VI 

CONDITIONS TO THE COMPANY’S OBLIGATION TO CLOSE 

The obligation of the Company hereunder to consummate the Closing is subject to the satisfaction or waiver by the Company, at or before the
Closing Date, of each of the following conditions: 
 Section 6.1 Execution of Transaction Documents. The Purchaser shall have
duly executed and delivered to the Company the Transaction Documents to which it is a party. 

  
 21 













 Section 6.2 Representations and Warranties; Covenants. The representations and
warranties of the Purchaser contained in Article III hereof shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality or material adverse effect, which shall be true and
correct to such extent) as of the date of this Agreement and as of the Closing Date as though made at that date (except for those representations and warranties that speak as of a specific date, which shall be so true and correct in all material
respects as of such specified date); provided that each representation or warranty made by the Purchaser in Sections 3.1, 3.2 and 3.3(a) shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as
though made at that date (except for those representations and warranties that speak as of a specific date, which shall be so true and correct as of such specified date); and the Purchaser shall have performed, satisfied and complied in all material
respects with the covenants and agreements required by this Agreement to be performed, satisfied or complied with by the Purchaser at or prior to the Closing Date. 

Section 6.3 No Stop Order. No stop order suspending the qualification or exemption from qualification of the Purchased Securities
in any jurisdiction shall have been issued and no Proceeding for that purpose shall have been commenced or shall be pending or threatened. 

Section 6.4 No Action. No Law or Judgment entered by or with any Governmental Authority with competent jurisdiction, shall be in
effect that enjoins, prohibits or materially alters the terms of the transactions contemplated by the Transaction Documents, nor any Proceeding challenging any Transaction Document or the transactions contemplated hereby and thereby, or seeking to
prohibit, alter, prevent or delay the Closing, shall have been instituted or being pending before any Governmental Authority. 

Section 6.5 Purchaser Officer’s Certificates. The Purchaser shall have delivered to the Company a
certificate (the “Purchaser Closing Certificate”), dated as of the Closing Date, executed by a duly authorized officer of the Purchaser, certifying to the fulfillment of the condition specified in Article VI. 

ARTICLE VII 
 CONDITIONS
TO THE PURCHASER’S OBLIGATION TO CLOSE 
 The obligation of the Purchaser hereunder to consummate the Closing is subject to the
satisfaction or waiver by the Purchaser, at or before the Closing Date, of each of the following conditions: 
 Section 7.1
Execution of Transaction Documents. The Company shall have duly executed and delivered to the Purchaser the Transaction Documents to which it is a party. 

Section 7.2 Representations and Warranties; Covenants. The representations and warranties of the Company contained in Article IV
hereof shall be true and correct in all material respects (except for those representations and warranties that are qualified by materiality or Material Adverse Effect, which shall be true and correct to such extent) as of the date of this Agreement
and as of the Closing Date as though made at that date (except for those representations and warranties that speak as of a specific date, which shall be so true and correct in all material respects as of such specified date); provided that
each representation or warranty made by the Company in this Agreement under Sections 4.1, 4.2, 4.3, 4.4(a) and 4.6 shall be true and correct in all respects as of the date of this Agreement and as of the Closing Date as though made at that date
(except for those representations and warranties that speak as of a specific date, which shall be so true and correct as of such specified date), and the Company shall have performed, satisfied and complied in all material respects with the
covenants and agreements required by this Agreement to be performed, satisfied or complied with by the Company at or prior to the Closing Date. 

  
 22 













 Section 7.3 No Stop Order. No stop order suspending the qualification or
exemption from qualification of the Purchased Securities in any jurisdiction shall have been issued and no Proceeding for that purpose shall have been commenced or shall be pending or threatened. 

Section 7.4 No Action. No Law or Judgment entered by or with any Governmental Authority with competent jurisdiction, shall be in
effect that enjoins, prohibits or materially alters the terms of the transactions contemplated by the Transaction Documents, nor Proceeding challenging any Transaction Document or the transactions contemplated hereby and thereby, or seeking to
prohibit, alter, prevent or delay the Closing, shall have been instituted or being pending before any Governmental Authority. 

Section 7.5 No Material Adverse Effect. From and after the date hereof, there shall not have occurred a Material Adverse Effect.

 Section 7.6 No Suspensions of Trading in ADSs. Trading in the ADSs has not been, or been threatened to be, suspended by the
SEC or Nasdaq as of the Closing Date. 
 Section 7.7 License Agreement. The Purchaser shall have the opportunity to examine a
scan copy of the signed signature pages of the respective parties to the License Agreement. 
 Section 7.8 Company
Officer’s Certificate. The Company shall have delivered to the Purchaser a certificate (the “Company Closing Certificate”), dated as of the Closing Date, executed by a duly authorized officer of the
Company, certifying to the fulfillment of the conditions specified in Article VII. 
 ARTICLE VIII 

TERMINATION 

Section 8.1 Termination. Subject to Section 8.2 below, this Agreement may be terminated and the transactions contemplated by
this Agreement abandoned at any time prior to the Closing: 
 (a) by mutual agreement of the Company and the Purchaser; 

(b) by the Company or the Purchaser if any Law, or any final, non-appealable injunction or order shall
have been enacted, issued, promulgated, enforced or entered which is in effect and has the effect of prohibiting the sale and issuance of the Purchased Securities, provided, however, that the right to terminate this Agreement pursuant to this
Section 8.1(b) shall not be available to a party if the issuance of such Law, injunction or order was primarily due to the breach or failure of such party to perform in material respects any of its obligations under this Agreement; 

  
 23 













 (c) by the Purchaser if there has been a material breach of any representation or warranty
by the Company under this Agreement or any material breach of any covenant or agreement by the Company under this Agreement that, in any case, would give rise to the failure of the condition set forth in Section 7.2 or Section 7.5, and
such breach is not cured within ten (10) Business Days upon delivery of written notice thereof from the Purchaser; provided, however, that the Purchaser shall not have the right to terminate this Agreement pursuant to this
Section 8.1(c) if the Purchaser shall have materially breached or failed to perform any of its representations, warranties, covenants or agreements under this Agreement and such breach or failure shall have been the principal cause of, or shall
have resulted in, the failure of the condition set forth in Section 7.2 or Section 7.5; 
 (d) by the Company if there has been a
material breach of any representation or warranty by the Purchaser under this Agreement or any material breach of any covenant or agreement by the Purchaser under this Agreement that, in any case, would give rise to the failure of the condition set
forth in Section 6.2, and such breach is not cured within ten (10) Business Days upon delivery of written notice thereof from the Company; provided, however, that the Company shall not have the right to terminate this Agreement
pursuant to this Section 8.1(d) if the Company shall have materially breached or failed to perform any of its representations, warranties, covenants or agreements under this Agreement and such breach or failure shall have been the principal
cause of, or shall have resulted in, the failure of the condition set forth in Section 6.2; or 
 (e) by the Company or the Purchaser,
upon written notice to the other parties if the Closing has not occurred within thirty (30) days of the date hereof, provided, however, that the right to terminate this Agreement under this Section 8.1(e) shall not be available to
any party whose failure to fulfill any obligation under this Agreement shall have been the principal cause of, or shall have resulted in, the failure of the Closing to occur on or prior to such date. 

Section 8.2 Effect of Termination. In the event of termination of this Agreement as provided in Section 8.1 above, written
notice thereof shall be given to the other party specifying the provision hereof pursuant to which such termination is made, and this Agreement shall forthwith become void and there shall be no liability or obligation on the part of the parties
hereto; provided that (a) nothing herein shall relieve any party hereto from liability for any breach of this Agreement that occurred before such termination and (b) the provisions of this Article VIII, Article IX, Section 5.3
and Section 5.8 shall remain in full force and effect and survive any termination of this Agreement pursuant to the terms of this Article VIII. 

ARTICLE IX 

MISCELLANEOUS 

Section 9.1 Survival. Other than the representations and warranties set forth in Sections 3.1, 3.2, 3.3(a), 4.1, 4.2, 4.3, 4.4(a)
and 4.6, which shall survive the Closing indefinitely, the representations and warranties of the parties set forth in Articles III and IV of this Agreement shall survive the execution and delivery of this Agreement and the Closing until the date
that is 12 months after the Closing; provided that each representation, warranty, covenant and agreement hereunder shall survive the Closing indefinitely in the case of fraud, intentional concealment of material facts or other willful
misconduct on the part of the Company or the Purchaser, as the case may be; provided, further, that a claim with respect to recovery under the indemnification provisions set forth in Section 9.2 is initiated prior to the
applicable survival period set forth in this Section 9.1, such claim may continue indefinitely until it is finally resolved pursuant to Section 9.2. 

  
 24 













 Section 9.2 Indemnification. From and after the Closing Date, each party (the
“Indemnitor”) shall defend, protect, indemnify and hold harmless the other parties and their respective Affiliates, shareholders, partners, members, officers, directors, employees, agents or other representatives (collectively, the
“Indemnitees”) from and against any and all actions, causes of action, suits, claims, losses, diminution in value, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether any
such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’ fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or
arising out of, or relating to (a) any misrepresentation or breach of any representation or warranty made by the Indemnitor in this Agreement and other Transaction Documents, (b) any breach of any covenant, agreement or obligation of the
Indemnitor contained in this Agreement or the other Transaction Documents, and (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party arising out of or as a result of any breach of any representation or
warranty made by the Indemnitor or any breach of any covenant, agreement or obligation of the Indemnitor under the Transaction Documents. Notwithstanding the foregoing, the term “Indemnified Liabilities” shall not include any punitive,
incidental, consequential, special or indirect losses and damages, including loss of future revenue or income, or loss of business reputation or opportunity. 

Section 9.3 Limitation to the Indemnitor’s Liability. Notwithstanding anything to the contrary in this
Agreement: 
 (a) the Indemnitor shall have no liability to the Indemnitees under Section 9.2(a) with respect to any misrepresentation
or breach of any representation or warranty made by the Indemnitor in this Agreement unless the aggregate amount of Indemnified Liabilities suffered or incurred by the Indemnitees thereunder exceeds five percent (5%) of the Aggregate Purchase Price,
in which case the Indemnitor shall be liable for all Indemnified Liabilities pursuant to Section 9.2(a); provided that, the limitation under this Section 9.3(a) shall not apply to any Indemnifiable Liabilities resulting from or
arising out of, directly or indirectly, fraud, intentional concealment of material facts or other willful misconduct on the part of the Indemnitor; 

(b) the maximum aggregate liabilities of the Indemnitor in respect of Indemnified Liabilities pursuant to Section 9.2(a) with respect to
any misrepresentation or breach of any representation or warranty made by the Indemnitor in this Agreement shall be subject to a cap equal to the Aggregate Purchase Price; provided that, the cap under this Section 9.3(b) shall not apply
to any Indemnifiable Liabilities resulting from or arising out of, directly or indirectly, fraud, intentional concealment of material facts or other willful misconduct on the part of the Indemnitor; 

  
 25 













 (c) notwithstanding any other provision contained herein and except in the case of fraud,
intentional misrepresentation and/or willful misconduct, from and after the Closing, this Section 9.3 shall be the sole and exclusive monetary remedy of any of the Indemnitees for any claims against the Indemnitor arising out of or resulting
from this Agreement and the other Transaction Documents and the transactions contemplated hereby and thereby; provided that the Indemnitee shall also be entitled to specific performance or other equitable remedies in any court of competent
jurisdiction pursuant to Section 9.15 hereof; provided, further, that the foregoing shall not limit the Indemnitee’s right to seek indemnification pursuant to paragraph 7 of Annex A; and 

(d) the representations, warranties, covenants, agreements and obligations of the Indemnitor, and the Indemnitee’s right to
indemnification with respect thereto, shall not be affected or deemed waived by reason of any investigation made by or on behalf of the Indemnitee (including by any of its agents or representatives) or by reason of the fact that the Indemnitee (or
any of its agents or representatives) knew or should have known that any such representation, warranty, covenant, agreement or obligation is, was or might be inaccurate or by reason of the Indemnitee’s waiver of any condition set forth Article
VII. 
 Section 9.4 Governing Law. This Agreement shall be governed by, and construed in accordance with, the laws of the State
of New York, without regard to principles of conflict of laws thereunder. 
 Section 9.5 Arbitration. 

(a) Any dispute, controversy, difference or claim arising out of or relating to this letter agreement, including the existence, validity,
interpretation, performance, breach or termination thereof or any dispute regarding non-contractual obligations arising out of or relating to it shall be referred to and finally resolved by arbitration
administered by the Hong Kong International Arbitration Centre (“HKIAC”) under the HKIAC Administered Arbitration Rules in force when the Notice of Arbitration is submitted. 

(b) The seat of arbitration shall be Hong Kong. 

(c) The number of arbitrators shall be three. The arbitrators shall be appointed in accordance with the HKIAC rules. The arbitration
proceedings shall be conducted in English. 
 (d) It shall not be incompatible with this arbitration agreement for any party to seek interim
or conservatory relief from courts of competent jurisdiction before the constitution of the arbitral tribunal. 
 Section 9.6
Counterparts. This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the
other parties. A facsimile or “PDF” signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original. The parties irrevocably and unreservedly
agree that this Agreement may be executed by way of electronic signatures and the parties agree that this Agreement, or any part thereof, shall not be challenged or denied any legal effect, validity and/or enforceability solely on the ground that it
is in the form of an electronic record. 

  
 26 













 Section 9.7 Severability. If any provision of this Agreement is found to be
invalid or unenforceable, then such provision shall be construed, to the extent feasible, so as to render the provision enforceable and to provide for the consummation of the transactions contemplated hereby on substantially the same terms as
originally set forth herein, and if no feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement, which shall remain in full force and effect unless the severed provision is essential to the rights
or benefits intended by the parties. In such event, the parties shall use commercially reasonable efforts to negotiate, in good faith, a substitute, valid and enforceable provision or agreement, which most nearly effects the parties’ intent in
entering into this Agreement. 
 Section 9.8 Entire Agreement. This Agreement and the other Transaction Documents, together with
all the schedules and exhibits hereto and thereto and the certificates and other written instruments delivered in connection therewith from time to time on and following the date hereof, constitute and contain the entire agreement and understanding
of the parties with respect to the subject matter hereof and thereof and supersedes any and all prior negotiations, correspondence, agreements, understandings, duties or obligations between the parties respecting the subject matter hereof and
thereof. 
 Section 9.9 Notices. Except as may be otherwise provided herein, any notices, consents, waivers or other
communications required or permitted to be given under the terms of this Agreement must be in writing and will be deemed to have been delivered: (a) upon receipt, when delivered personally; (b) upon receipt, when sent by facsimile
(provided confirmation of transmission is mechanically or electronically generated and kept on file by the sending party); or (c) one (1) Business Day after deposit with an internationally recognized overnight courier service; or
(d) when sent by confirmed electronic mail if sent during normal business hours of the recipient, or if not, then on the next Business Day, in each case properly addressed to the party to receive the same. The addresses and facsimile numbers
for such communications shall be: 
 If to the Company: 
  

			
	 Address:
	  	 Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District

Shanghai, 201210, People’s Republic of China

	 Telephone:
	  	 +86 21-6057-8000

	 Email:
	  	 jielun.zhu@i-mabbiopharma.com

	 Attention:
	  	 Jielun Zhu

	
	with a copy (for informational purposes only) to:
	
	Wilson Sonsini Goodrich & Rosati, Professional Corporation
	 Address:
	  	 Unit 2901, 29F, Tower C, Beijing Yintai Centre

		  	 No. 2 Jianguomenwai Avenue, Chaoyang District

		  	 Beijing, 100022, People’s Republic of China

	 Email:
	  	 douyang@wsgr.com; keli@wsgr.com

	 Telephone:
	  	 +86 10-6529-8300

	 Attention:
	  	 Dan Ouyang; Ke Li



  
 27 














			
	
	 If to the Purchaser:

		
	 Address:
	  	 [            ]

	 Email:
	  	 [            ]

	 Facsimile:
	  	 [            ]

	 Attention:
	  	 [            ]



 A party may change or supplement the addresses given above, or designate additional addresses, for purposes of this
Section 9.9 by giving the other parties written notice of the new address in the manner set forth above. 
 Section 9.10 No
Third-Party Beneficiaries. This Agreement shall be binding upon and inure solely to the benefit of, and be enforceable by, only the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is
intended to or shall confer upon any other Person (other than the Indemnitees) any right, benefit or remedy of any nature whatsoever under or by reason of this Agreement, except that the Placement Agent shall be a third party beneficiary of Articles
III and IV of this Agreement and may rely on each representation and warranty of the Purchaser and the Company made herein or pursuant to the terms hereof (including the Company Closing Certificate and the Purchaser Closing Certificate) with the
same force and effect as if such representation or warranty were made directly to the Placement Agent. 
 Section 9.11 Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of, and shall be binding upon, the successors and permitted assigns of the parties hereto. Except as otherwise provided herein, neither this Agreement nor any of the
rights, interests, or obligations hereunder shall be assigned by any party hereto (whether by operation of law or otherwise) without the prior written consent of the other party; provided, however, that the Purchaser may assign any of its
rights, interests, or obligations hereunder to an Affiliate of the Purchaser without the prior written consent of the Company. 

Section 9.12 Construction. Each of the parties has participated in the drafting and negotiation of this Agreement. If an ambiguity
or question of intent or interpretation arises, this Agreement must be construed as if it is drafted by all the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of authorship of any of the
provisions of this Agreement. 
 Section 9.13 Further Assurances. Each party shall do and perform, or cause to be done and
performed, all such further acts and things, and shall execute and deliver all such other agreements, certificates, instruments and documents, as any other party may reasonably request in order to carry out the intent and accomplish the purposes of
this Agreement and the consummation of the transactions contemplated hereby. 
 Section 9.14 Adjustment of Share Numbers. If
there is a subdivision, split, stock dividend, combination, reclassification or similar event with respect to any of the shares of Company’s Ordinary Shares referred to in this Agreement, then, in any such event, the numbers and types of shares
of such Ordinary Shares, as applicable, referred to in this Agreement shall be adjusted to the number and types of shares of such stock that a holder of such number of shares of such stock would own or be entitled to receive as a result of such
event of such holder had held such number of shares immediately prior to the record date for, or effectiveness of, such event. 

  
 28 













 Section 9.15 Specific Performance. The parties hereto acknowledge and agree
irreparable harm may occur for which money damages would not be an adequate remedy in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly
agreed that, in addition to any other remedies at law or in equity, the parties to this Agreement shall be entitled to injunction to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement without
posting any bond or other undertaking. 
 Section 9.16 Amendment; Waiver. This Agreement may be amended, modified or
supplemented only by a written instrument duly executed by all the parties hereto. The observance of any provision in this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively) only by the
written consent of the party against whom such waiver is to be effective. Any amendment or waiver effected in accordance with this Section 9.16 shall be binding upon the Company and the Purchaser and their respective assigns. It is agreed that
no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, shall impair any such right, power or remedy, nor shall it be construed to be a
waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. 

[Signature Page Follows] 
  

  
 29 













 IN WITNESS WHEREOF, the parties hereto have caused their respective signature page to
this Agreement to be duly executed as of the date first written above. 
  

	
	I-MAB
	
	By: _______________________
	Name:
	Title:


 [Signature Page to Subscription Agreement] 












 IN WITNESS WHEREOF, the parties hereto have caused their respective signature page to
this Agreement to be duly executed as of the date first written above. 
  

	
	[Name of Investor]
	
	 By: _______________________

	 Name:

	 Title:



 [Signature Page to Subscription Agreement] 












 Schedule A 

List of Subsidiaries 
  

			
	 Name of Subsidiary
	  	 Place of Incorporation

	I-Mab Biopharma Hong Kong Limited	  	Hong Kong
	I-Mab Biopharma US Ltd.	  	United States
	I-Mab Bio-tech (Tianjin) Co., Ltd.	  	People’s Republic of China
	I-Mab Biopharma Co., Ltd.	  	People’s Republic of China
	I-Mab Bio-tech (Hangzhou) Co., Ltd.	  	People’s Republic of China
	Chengdu Tasgen Bio-tech Co., Ltd.	  	People’s Republic of China
	Shanghai Tianyunjian Bio-tech Co., Ltd.	  	People’s Republic of China
	Thirdventure Beijing Bio-tech Co., Ltd.	  	People’s Republic of China

 Schedule A to Subscription Agreement  












 Schedule B 

Company Bank Account 

Schedule B to Subscription Agreement  
  












 Annex A 

Registration Rights 
 The
Purchaser shall be entitled to the following rights with respect to the Registrable Securities. 
  

	1.	 Mandatory Registration. 



 

	 	(a)	 The Company agrees to file with the SEC a registration statement to register under and in accordance with the
provisions of the Securities Act, the resale of the Purchaser’s Registrable Securities on Form F-3 or Form F-1, which shall be the sole decision of the Company
(which shall be filed pursuant to Rule 415 under the Securities Act as a secondary-only registration statement), if the Company is then eligible for such short form, or any similar or successor short form registration or, if the Company is not then
eligible for such short form registration or would not be able to register for resale all of the Registrable Securities on Form F-3, on Form F-1 or any similar or
successor long form registration (the “Registration Statement”). The Company shall use its commercially reasonable efforts to have the Registration Statement declared effective by the SEC as soon as practicable after the filing
thereof, but no later than ninety (90) calendar days after the Closing Date (the “Effectiveness Deadline”); provided that the Effectiveness Deadline shall be extended to one hundred and twenty (120) calendar days
after the Closing Date if the Registration Statement is reviewed by, and receives comments from, the SEC; provided, further, that the Company’s obligations to include the Purchaser’s Registrable Securities in the Registration
Statement are contingent upon the Purchaser’s furnishing in writing to the Company such information regarding the Purchaser, the Registrable Securities held by the Purchaser and the intended method of disposition of the Registrable Securities
as shall be reasonably requested by the Company to effect the registration of the Registrable Securities, and shall execute such documents in connection with such registration as the Company may reasonably request that are customary of a selling
shareholder in similar situations. The Company will provide a draft of the Registration Statement to the Purchaser for review at least two (2) Business Days in advance of filing the Registration Statement. In no event shall the Purchaser be
identified as a statutory underwriter in the Registration Statement unless requested by the SEC. 


  

	 	(b)	 Notwithstanding the foregoing, if the SEC prevents the Company from including any or all of the Registrable
Securities proposed to be registered under the Registration Statement due to limitations on the use of Rule 415 under the Securities Act for the resale of the Registrable Securities by the Purchaser or otherwise, such Registration Statement shall
register for resale such number of Purchaser which is equal to the maximum number of the Securities as is permitted by the SEC. In such event, the number of the Registrable Securities to be registered for each selling shareholder named in the
Registration Statement shall be reduced pro rata among all such selling shareholders; provided that the Securities of the Investors and Holders (as defined in the Fourth Amended and Restated Shareholders Agreement of the Company dated
July 25, 2019 (the “Shareholders Agreement”) shall all be included in such Registration Statement pursuant to the terms of the Shareholders Agreement before the inclusion of the Registrable Securities to be registered for the
Purchaser. 


 Schedule A to Subscription Agreement  













	 	(c)	 The Company will use its commercially reasonable efforts to maintain the continuous effectiveness of the
Registration Statement for a period of ninety (90) days after the effectiveness of the Registration Statement or such shorter period upon which the Purchaser has notified the Company that its Registrable Securities have actually been sold. The
period of time during which the Company is required hereunder to keep a Registration Statement effective is referred to herein as the “Registration Period.” The Company will use its commercially reasonable efforts to (i) cause
the removal of all restrictive legends from any Purchased Shares being sold under the Registration Statement no later than ten (10) Business Days after the effectiveness thereof, subject to the requirements under applicable securities Laws
and/or from the Company’s depositary bank administering the relevant ADS program, or pursuant to Rule 144 under the Securities Act (“Rule 144”) at the time of sale of such Registrable Securities and, at the request of the
Purchaser, cause the removal of all restrictive legends from any Registrable Securities held by the Purchaser that may be sold by the Purchaser without restriction under Rule 144, including without limitation, any volume and manner of sale
restrictions, and (ii) cause its legal counsel to deliver the necessary legal opinions, if any, to the transfer agent in connection with the instruction under subclause (i) upon the receipt of such supporting documentation, if any, as
reasonably requested by such counsel. For the avoidance of doubt, nothing in the immediately preceding sentence shall relieve the Company of any obligations under Section 5.7 of this Agreement. The Company will use commercially reasonable
efforts to file all reports, and provide all customary and reasonable cooperation, reasonably necessary to enable the Purchaser to resell Registrable Securities pursuant to the Registration Statement or Rule 144, as applicable, qualify the
Registrable Securities for listing on the applicable stock exchange and update or amend the Registration Statement as necessary to include Registrable Securities. 



 

	 	(d)	 For purposes of this Annex, “Registrable Securities” shall mean the Purchased Shares and the
Warrant Shares (if any) (whether held in the form of ADSs or Ordinary Shares), including any ADSs or Ordinary Shares issuable with respect to the Purchased Securities by way of a dividend, share split or other distribution, or in connection with a
combination of shares, recapitalization, merger, consolidation or other reorganization; provided that such Registrable Securities shall not be considered to be Registrable Securities (i) at any time that (but only during such time as)
such security is eligible to be sold pursuant to Rule 144 without condition or restriction, including without any limitation as to volume of sales, and without the Purchaser complying with any method of sale requirements or notice requirements under
Rule 144, or (ii) if such Securities have been sold pursuant to an effective registration statement or in compliance with Rule 144 or other exemptions from registration; provided, further, that paragraph 1(a) (Mandatory
Registration) of this Annex A shall not be available to the Purchaser with respect to the Warrant Shares (if any). 



Schedule A to Subscription Agreement  













	2.	 Piggyback Registration. 



 

	 	(a)	 The Company shall notify the Purchaser in writing at least thirty (30) days prior to filing any
registration statement under the Securities Act for purposes of effecting a public offering of ADSs (including registration statements relating to secondary offerings of ADSs, but excluding registration statements relating to the Mandatory
Registration described in paragraph 1(a) of this Annex A or to any employee benefit plan or a corporate reorganization) (such notice, the “Registration Rights Notice”) and shall afford the Purchaser an opportunity to include in such
registration statement all or any part of the Registrable Securities then held by the Purchaser which have not been previously registered pursuant to an effective registration statement. The Purchaser desiring to include in any such registration
statement such Registrable Securities shall within twenty (20) days after receipt of the above-described notice from the Company, so notify the Company in writing, and in such notice shall inform the Company of the number of Registrable
Securities the Purchaser wishes to include in such registration statement. The Purchaser shall be permitted to withdraw all or any part of such Registrable Securities from any registration at any time prior to the effective date of such
registration, except as otherwise provided in any written agreement with the Company’s underwriter(s) establishing the terms and conditions under which the Purchaser would be obligated to sell such Registrable Securities in such registration.
The right contained in this paragraph 2(a) may be exercised by the Purchaser only with respect to two (2) qualifying registrations. 


  

	 	(b)	 If the registration under the preceding paragraph 2(a) is for a registered public offering that is to be made
by an underwriting, the Company shall so advise the Purchaser as part of the Registration Rights Notice. In that event, the right of the Purchaser to such registration shall be conditioned upon its participation in such underwriting and the
inclusion of its Registrable Securities in the underwriting to the extent provided herein. If the Purchaser proposes to sell any of its Registrable Securities through such underwriting, it shall (together with the Company and any other shareholders
of the Company selling their Securities through such underwriting) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting by the Company or such other selling shareholders, as applicable.
Notwithstanding any other provision of this paragraph 2(b), if the underwriter(s) or the Company determines that marketing factors require a limitation on the number of Securities to be underwritten, the underwriter(s) may exclude some or all
Registrable Securities from such registration and underwriting. The Company shall so advise the Purchaser, unless it has failed to include its Registrable Securities through such underwriting or has indicated to the Company its decision not to do
so, and indicate to the Purchaser the number of the Registrable Securities that may be included in the registration and underwriting, if any. The number of Securities to be included in such registration and underwriting shall be allocated
first to the Company and each of the Holders (as defined in the Shareholders Agreement) in accordance with the terms of the Shareholders Agreement; second, to the investors in the Private Placements (including the Purchaser) demanding
registration of, or requesting inclusion of, their Registrable Securities (as defined in their respective subscription agreement in connection with the Private Placements) in such registration statement on a pro rata basis based on the total number
of Registrable Securities (as defined in their respective subscription agreement in connection with the Private Placements) then held by each such investor; and third, to other holders of Securities, if any. For the avoidance of doubt, the
right of the underwriter(s) to exclude shares (including the Registrable Securities) from the registration and underwriting as described above shall be restricted so that all shares that are held by any employee, officer or director of the Company
or any Subsidiary thereof shall first be excluded from such registration and underwriting before any Registrable Securities are so excluded unless otherwise approved by the holders of the majority of Registrable Securities (as defined in the
investors’ respective subscription agreement in connection with the Private Placements). 


 Schedule A to Subscription
Agreement  













	 	(c)	 No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing
limitation shall be included in such registration. If the Purchaser disapproves of the terms of any such underwriting, such Purchaser may elect to withdraw its Registrable Securities therefrom by delivering a written notice to the Company at least
ten (10) Business Days prior to the effective date of the registration statement. 


  

	3.	 Suspension of Registration. Notwithstanding anything to the contrary contained herein, the Company may,
upon written notice, suspend the use of any registration statement, including any prospectus that forms a part of a registration statement, if the Company (i) determines in good faith that it would be required to make disclosure of material
information in the registration statement that the Company has a bona fide business purpose for preserving as confidential; (ii) the Company determines it must amend or supplement the registration statement or the related prospectus so that
such registration statement or prospectus shall not include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of
the circumstances under which they were made, not misleading; or (iii) the Company has experienced or is experiencing some other material non-public event, including a pending transaction involving the
Company, the disclosure of which at such time, in the good faith judgment of the Company, would adversely affect the Company; provided, however, in no event shall sales of Registrable Securities be suspended pursuant to the registration
statement for a period that exceeds thirty (30) consecutive trading days (any such suspension contemplated by this paragraph 3, an “Allowed Delay”); provided, further, that the Company may not utilize this right
more than once in any twelve (12) month period and may not register any other Securities during any Allowed Delay. Upon disclosure of such information or the termination of the condition described above, the Company shall provide prompt notice
to the Purchaser and shall promptly terminate any suspension of sales it has put into effect and shall take such other reasonable actions to permit registered sales of Registrable Securities as contemplated hereby. The Purchaser agrees that, upon
receipt of any notice from the Company of an Allowed Delay, the Purchaser will immediately discontinue disposition of Registrable Securities pursuant to any registration statement covering such Registrable Securities, until the Purchaser is advised
by the Company that such dispositions may again be made. 


 Schedule A to Subscription Agreement  













	4.	 Expenses. All expenses incurred in connection with registrations, filings or qualifications pursuant to
this Annex A, including all registration, filing and qualification fees (including “blue sky” fees and expenses); printers’ and accounting fees; fees and disbursements of counsel for the Company shall be borne and paid by the Company,
except that any (i) fees and disbursements of counsel for the Purchaser acting as selling shareholder counsel, and (ii) discounts, commissions, fees of underwriters, selling brokers, dealer managers or similar securities industry
professionals applicable to the sale of any of the Registrable Securities. 


  

	5.	 Rule 144. With a view to making available to the Purchaser the benefits of Rule 144, the Company
covenants that it will use commercially reasonable efforts to (i) file in a timely manner all reports and other documents required, if any, to be filed by it under the Securities Act and the Exchange Act and the rules and regulations adopted
thereunder and (ii) make available information necessary to comply with Rule 144 with respect to resales of the Registrable Securities under the Securities Act, at all times, to the extent required from time to time to enable the Purchaser to
resell the Registrable Securities without registration under the Securities Act within the limitation of the exemptions provided by Rule 144 (if available with respect to resales of the Registrable Securities), as such rule may be amended from time
to time. 


  

	6.	 Purchaser’s Covenants. The Purchaser shall furnish in writing to the Company such information
regarding itself, the Registrable Securities and the intended method of disposition of the Registrable Securities, as shall be reasonably requested to effect the registration of such Registrable Securities and shall execute such documents in
customary form in connection with such registration as the Company may reasonably request. The Purchaser, by its acceptance of the Registrable Securities, agrees to cooperate with the Company as reasonably requested by the Company in connection with
the preparation and filing of a registration statement and/or prospectus hereunder, provided that the Purchaser shall be given the opportunity to review and comment on such registration statement and/or prospectus. 



 

	7.	 Indemnification.  



 

	 	(a)	 To the extent permitted by Law, the Company will indemnify and hold harmless the Purchaser and its officers,
directors, partners, members, employees and agents, successors and assigns, and each other Person, if any, who controls the Purchaser (within the meaning of the Securities Act), against any losses, claims, damages or liabilities, joint or several,
to which they may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) that arise out of or are based upon any untrue statement or alleged untrue statement of
any material fact or omission or alleged omission of any material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading,
contained in any registration statement, any preliminary prospectus or final prospectus, or any amendment or supplement thereof; provided, however, that the Company will not be liable in any such case if and to the extent that any such loss, claim,
damage or liability arises out of or is based upon (i) an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by the Purchaser or any such controlling Person in writing
specifically for use in such registration statement or prospectus and which information has not been corrected in a subsequent writing prior to or concurrently with the sale of the applicable Securities, (ii) the use by the Purchaser of an
outdated or defective prospectus after the Company has notified the Purchaser in writing that such prospectus is outdated or defective, or (iii) the Purchaser’s failure to send or give a copy of the prospectus or supplement (as then
amended or supplemented), if required (and not exempted) to the Persons asserting an untrue statement or omission or alleged untrue statement or omission at or prior to the written confirmation of the sale of the applicable Securities.



 Schedule A to Subscription Agreement  













	 	(b)	 To the extent permitted by Law, the Purchaser will indemnify and hold harmless the Company, its directors,
officers, employees, shareholders and each Person who controls the Company (within the meaning of the Securities Act) against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) that arise out of or are based
upon any untrue statement or alleged untrue statement of any material fact or omission or alleged omission of any material fact required to be stated therein or necessary to make the statements therein, in the case of the prospectus in light of the
circumstances under which they were made, not misleading, contained in any registration statement, any preliminary prospectus or final prospectus, or any amendment or supplement thereof, to the extent, but only to the extent, that such untrue
statement or omission is contained in any information regarding the Purchaser and furnished in writing by the Purchaser to the Company specifically for inclusion in such registration statement or prospectus or amendment or supplement thereto, and
which information has not been corrected in a subsequent writing prior to or concurrently with the sale of the applicable Securities, provided, however, that the indemnity agreement contained in this paragraph 7(b) shall not apply to
amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Purchaser, which consent shall not be unreasonably withheld; and provided, further, that in no
event shall any indemnity under this paragraph 7(b) exceed the net proceeds received by such Purchaser in such registered offering. 



Schedule A to Subscription Agreement  













	 	(c)	 Any Person entitled to indemnification hereunder shall (i) give prompt notice to the indemnifying party of
any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; provided, that any Person entitled to
indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such Person unless (A) the indemnifying party has
agreed to pay such fees or expenses, (B) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such Person or (C) in the reasonable judgment of any such Person, based
upon written advice of its counsel, a conflict of interest exists between such Person and the indemnifying party with respect to such claims (in which case, if the Person notifies the indemnifying party in writing that such Person elects to employ
separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such Person); and provided, further that the failure of any indemnified party
to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim
or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified
parties. No indemnifying party will, except with the consent of the indemnified party, which shall not be unreasonably withheld or conditioned, consent to entry of any judgment or enter into any settlement that does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. 


  

	 	(d)	 If for any reason the indemnification provided for in the preceding paragraphs 7(a) and (b) is unavailable
to an indemnified party or insufficient to hold it harmless, other than as expressly specified therein, then the indemnifying party shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or
liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations. No Person guilty of fraudulent misrepresentation within the
meaning of Section 11(f) of the Securities Act shall be entitled to contribution from any Person not guilty of such fraudulent misrepresentation. In no event shall the contribution obligation of a holder of Registrable Securities be greater in
amount than the dollar amount of the proceeds received by it upon the sale of the Registrable Securities giving rise to such contribution obligation. 


  

	8.	 Ranking of Registration Rights. The Purchaser acknowledges that any registration rights granted to, or
created for the benefit of, the Purchaser under this Annex A shall not be senior to, or on a parity with, those granted to the Holders (as defined therein) under the Shareholders Agreement. 



Schedule A to Subscription Agreement  












 Annex B 

Form of Cayman Legal Opinion 

Annex B to Subscription Agreement  












 Annex C 

Form of Warrant 
 Annex C
to Subscription Agreement